ABILIFY MYCITE KIT Drug Patent Profile

Which patents cover Abilify Mycite Kit, and when can generic versions of Abilify Mycite Kit launch?

Abilify Mycite Kit is a drug marketed by Otsuka and is included in one NDA. There are twenty-seven patents protecting this drug.

This drug has five hundred and thirteen patent family members in forty-two countries.

The generic ingredient in ABILIFY MYCITE KIT is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Abilify Mycite Kit

A generic version of ABILIFY MYCITE KIT was approved as aripiprazole by ALEMBIC on April 28^th, 2015.

Summary for ABILIFY MYCITE KIT

International Patents:	513
US Patents:	27
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	125
Clinical Trials:	2
Patent Applications:	6,225
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ABILIFY MYCITE KIT
DailyMed Link:	ABILIFY MYCITE KIT at DailyMed

Recent Clinical Trials for ABILIFY MYCITE KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Otsuka Pharmaceutical Development & Commercialization, Inc.	NA
Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 4

See all ABILIFY MYCITE KIT clinical trials

US Patents and Regulatory Information for ABILIFY MYCITE KIT

ABILIFY MYCITE KIT is protected by twenty-seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-003	Nov 13, 2017		DISCN	Yes	No	9,941,931		Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-004	Nov 13, 2017		DISCN	Yes	No	9,119,554		Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		DISCN	Yes	No	9,149,577		Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017		DISCN	Yes	No	8,547,248		Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-006	Nov 13, 2017		DISCN	Yes	No	9,119,554		Y
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-004	Nov 13, 2017		DISCN	Yes	No	9,268,909		Y

Expired US Patents for ABILIFY MYCITE KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-005	Nov 13, 2017	9,089,567
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017	7,053,092
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-002	Nov 13, 2017	8,642,760
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-004	Nov 13, 2017	8,017,615
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-005	Nov 13, 2017	8,017,615
Otsuka	ABILIFY MYCITE KIT	aripiprazole	TABLET;ORAL	207202-005	Nov 13, 2017	8,580,796

EU/EMA Drug Approvals for ABILIFY MYCITE KIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)	aripiprazole	EMEA/H/C/003803Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-30
Otsuka Pharmaceutical Netherlands B.V.	Abilify	aripiprazole	EMEA/H/C/000471Abilify is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Abilify is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Abilify is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	no	no	no	2004-06-04
Otsuka Pharmaceutical Netherlands B.V.	Abilify Maintena	aripiprazole	EMEA/H/C/002755Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.	Authorised	no	no	no	2013-11-14
Accord Healthcare S.L.U.	Aripiprazole Accord	aripiprazole	EMEA/H/C/004021Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-11-15
Zentiva, k.s.	Aripiprazole Zentiva	aripiprazole	EMEA/H/C/003899Aripiprazole Zentiva is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Zentiva is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Zentiva is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.	Authorised	yes	no	no	2015-06-25
Sandoz GmbH	Aripiprazole Sandoz	aripiprazole	EMEA/H/C/004008Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older., , Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment., , Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.,	Authorised	yes	no	no	2015-08-20

International Patents for ABILIFY MYCITE KIT

See the table below for patents covering ABILIFY MYCITE KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	252946	מערכת פארמה-אינפורמטיקה (Pharma-informatics system)
Taiwan	I708590
Singapore	181489	INTEGRATED INGESTIBLE EVENT MARKER SYSTEM WITH PHARMACEUTICAL PRODUCT
Norway	336265
South Korea	20090115791	고 표면적 전극을 갖는 체내 전원 (IN-BODY POWER SOURCE HAVING HIGH SURFACE AREA ELECTRODE)
Taiwan	201317931

Supplementary Protection Certificates for ABILIFY MYCITE KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

Market Dynamics and Financial Trajectory for ABILIFY MYCITE KIT

Last updated: February 19, 2026

What is the current market status of ABILIFY MYCITE KIT?

ABILIFY MYCITE KIT (aripiprazole tablets with an ingestible sensor) was approved by the FDA in November 2017. It combines aripiprazole to treat schizophrenia, bipolar disorder, and major depressive disorder with an ingestible sensor that communicates medication intake to a connected device.

As of 2023, the product has not achieved broad market penetration. Sales performance has remained modest compared to oral aripiprazole formulations, partly due to high cost, limited insurance coverage, and user adoption challenges.

How does its market penetration compare to traditional aripiprazole formulations?

Formulation	Approximate Global Sales (2022)	Key Factors
Traditional oral aripiprazole	$3.2 billion	Widely prescribed, insurance coverage, established efficacy
ABILIFY MYCITE KIT	<$50 million	Limited adoption, high cost, regulatory hurdles

The traditional formulations dominate the antipsychotic market, with ABILIFY MYCITE representing less than 2% of total aripiprazole sales.

What factors influence the product’s financial outlook?

Regulatory and Healthcare Policies

• Preference for traditional medications persists.
• Reimbursement policies for digital health devices remain inconsistent.
• Insurance coverage for medicated digital devices is limited, affecting patient access.

Competitive Landscape

• Generics: Several generic aripiprazole products available with lower costs.
• Digital Medicine Alternatives: Other digital health solutions for medication adherence are emerging, but none have comparable combination products.

Technology Adoption

• Healthcare providers exhibit cautious adoption; digital health literacy varies.
• Patient acceptability is constrained by privacy concerns and device management.

Market Growth Drivers

• Increased interest in digital adherence tools.
• Potential expansion into other mental health conditions.
• Regulatory initiatives promoting digital health integration.

Market Barriers

• High development and manufacturing costs.
• Limited evidence of improved clinical outcomes over traditional formulations.
• Short product lifecycle potential due to generic competition.

What is the projected financial trajectory?

Projected revenue growth is modest in the next five years. Compound annual growth rate (CAGR) estimates range from 2% to 5%, contingent on regulatory changes, insurance coverage expansion, and technological advancements.

Year	Estimated Market Size	Key Assumptions
2023	<$50 million	Limited adoption, early-stage growth
2025	~$70 million	Slight increase in insurance coverage, provider familiarity
2030	~$100 million	Broader acceptance, improved reimbursement policies, expanded indications

The product's niche status is likely unless new clinical data convincingly demonstrate superiority or major policy shifts favor digital adherence tools.

How do regulatory and policy developments influence the financial prospects?

Regulatory Environment

• The FDA approved ABILIFY MYCITE under a new pathway for digital medicines, yet further approvals are limited.
• Pending revisions in Medicare and Medicaid coverage policies could influence reimbursement, directly affecting sales.

Policy Trends

• CMS (Centers for Medicare & Medicaid Services) has yet to incorporate digital medication adherence tools into standard coverage.
• Evolving policies could either facilitate broader adoption or exacerbate barriers, depending on the alignment with digital health goals.

How does pricing compare to traditional medications?

Aspect	Traditional Aripiprazole	ABILIFY MYCITE KIT
Price per dose	~$5-$10	~$60-$100, depending on insurance and payer negotiations
Reimbursement coverage	Common, well-established	Limited; varies by payer

The high cost limits uptake among payers and patients, especially in markets with constrained budgets.

What is the outlook for investments and R&D?

Investment in digital medicine remains strong. Companies focus on improving sensor accuracy, reducing costs, and demonstrating clinical benefits. However, ABILIFY MYCITE's specific trajectory appears constrained without breakthrough clinical or policy outcomes.

Key Challenges and Opportunities

Challenges	Opportunities
Limited reimbursement and insurance coverage	Expansion into new therapeutic areas
High manufacturing and R&D costs	Technological improvements in sensors
Resistance from providers and payers	Integration with digital health ecosystems

Key Takeaways

• ABILIFY MYCITE KIT holds a minor share of the overall aripiprazole market.
• Financial growth remains constrained, with projections favoring slow, steady expansion.
• Reimbursement policies and clinical proof of benefit are critical to future market uptake.
• Competition from traditional formulations and generics diminishes the product’s economic viability.
• Opportunities exist via technological innovation and broader digital health integration.

FAQs

1. What therapeutic areas could expand ABILIFY MYCITE’s market?
Potential expansion includes other psychiatric conditions such as bipolar disorder and major depressive disorder.

2. How does insurance coverage impact sales?
Limited insurance reimbursements restrict patient access, affecting overall sales.

3. What are the manufacturing cost implications?
Sensor integration adds to manufacturing complexity and costs, hampering profit margins.

4. Are clinical outcomes improved by the digital component?
Current evidence remains limited; clinical gains depend on improved adherence, but definitive data are sparse.

5. When might regulatory environments become more favorable?
Regulatory changes, especially in digital health reimbursement policies, could occur within the next 3-5 years, influencing market growth.

---

References

[1] Food and Drug Administration. (2017). FDA approves first digital medicine with sensor that 'confirms' medication ingestion.
[2] IQVIA. (2022). Global pharmaceutical sales report.
[3] Deloitte. (2021). Digital health market outlook.
[4] Centers for Medicare & Medicaid Services. (2023). Coverage policies for digital health solutions.